NIH starts Phase 3 trial of blood clotting treatments for COVID-19

The NIH announced today that it has launched the last of three Phase 3 clinical trials to evaluate blood thinners to prevent life-threatening blood clots in adults with COVID-19.

As part of the  Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, the trial will study the use of Bristol Myers Squibb/Pfizer’s Eliquis blood thinner in patients discharged from the hospital following a case of moderate-to-severe COVID-19. The other two ACTIV studies involve hospitalized and nonhospitalized COVID-19 adults.

The trials are taking place at more than 100 sites worldwide.

Researchers noticed early in the COVID-19 pandemic that many people who died have blood clots throughout their bodies — clotting that can cause multiple health complications ranging from organ damage to heart attack. The ACTIV-4 trials are meant to answer critical questions about properly use blood thinners or anticoagulants to treat COVID-19 cases.

 

---

Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: anticoagulants, Bristol-Myers Squibb, clinical trials, coronavirus, covid-19, Eliquis, NIH, Pfizer
 

---